← FDA Drug Approvals (Drugs@FDA)

RIVASTIGMINE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: MYLAN TECHNOLOGIES · Approved 2018-06-20

Drug application

FDA Application #

ANDA205622

Application type

Abbreviated New Drug Application (Generic)

Brand name

RIVASTIGMINE

Generic name

RIVASTIGMINE

Active ingredients

RIVASTIGMINE

Dosage form

FILM, EXTENDED RELEASE

Route

TRANSDERMAL

Marketing status

Prescription

Sponsor

MYLAN TECHNOLOGIES

Manufacturer

Mylan Pharmaceuticals Inc.

First approval

2018-06-20

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown